Physician profile
Peter A Naas
NPI 1215135199
$6,458.39
in general payments reported to CMS, 2019-2025
34 companies · $2,201 in 2025
The $2,201 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $119 · 2021: $166 · 2022: $964 · 2023: $1,226 · 2024: $1,242 · 2025: $2,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,535 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,534.90 |
| Education | $135.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,732.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $780.76 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $571.81 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $486.95 | 2022-2025 | Entyvio, Gattex |
| Pfizer INC. | $355.67 | 2019-2025 | |
| Ardelyx, INC. | $267.29 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $253.65 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $183.47 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $172.71 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $165.27 | 2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $127.84 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $110.73 | 2021-2025 | Givlaari |
| Celgene Corporation | $104.93 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $98.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $97.49 | 2022-2023 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $91.82 | 2022-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $85.19 | 2024-2025 | Iqirvo, Bylvay |
| Regeneron Healthcare Solutions, INC. | $83.40 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $82.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $81.94 | 2021-2024 | Dificid |
| Lilly USA, LLC | $79.76 | 2024-2025 | Omvoh |
| Lucid Diagnostics INC. | $76.55 | 2024 | |
| Gilead Sciences, INC. | $65.66 | 2022-2025 | |
| Ucb, INC. | $54.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.15 | 2023-2024 | Cyltezo |
| Medtronic, INC. | $44.78 | 2024-2025 | Gi Genius |
| Daiichi Sankyo INC. | $32.57 | 2022-2023 | Injectafer |
| Boston Scientific Corporation | $27.08 | 2025 | Apollo Esg Nxt System |
| Biocon Biologics INC | $18.09 | 2025 | Hulio |
| Redhill Biopharma INC. | $16.63 | 2021 | |
| Mylan Institutional INC. | $15.67 | 2023 | Hulio |
| Amgen INC. | $14.17 | 2022 | |
| W. L. Gore & Associates, INC. | $13.13 | 2022 | |
| Shire North American Group INC | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Naas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.